JP2012513193A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012513193A5 JP2012513193A5 JP2011541487A JP2011541487A JP2012513193A5 JP 2012513193 A5 JP2012513193 A5 JP 2012513193A5 JP 2011541487 A JP2011541487 A JP 2011541487A JP 2011541487 A JP2011541487 A JP 2011541487A JP 2012513193 A5 JP2012513193 A5 JP 2012513193A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- tfpi
- amino acids
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 claims 13
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 claims 13
- 150000001413 amino acids Chemical class 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 206010053567 Coagulopathies Diseases 0.000 claims 5
- 230000035602 clotting Effects 0.000 claims 5
- 239000008280 blood Substances 0.000 claims 4
- 210000004369 blood Anatomy 0.000 claims 4
- 230000002950 deficient Effects 0.000 claims 4
- 102000053391 human F Human genes 0.000 claims 4
- 108700031895 human F Proteins 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000031169 hemorrhagic disease Diseases 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000020971 positive regulation of blood coagulation Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08172522 | 2008-12-22 | ||
| EP08172522.8 | 2008-12-22 | ||
| PCT/EP2009/067566 WO2010072687A1 (en) | 2008-12-22 | 2009-12-18 | Antibodies against tissue factor pathway inhibitor (tfpi) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012513193A JP2012513193A (ja) | 2012-06-14 |
| JP2012513193A5 true JP2012513193A5 (OSRAM) | 2012-12-13 |
| JP5791512B2 JP5791512B2 (ja) | 2015-10-07 |
Family
ID=42104649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011541487A Expired - Fee Related JP5791512B2 (ja) | 2008-12-22 | 2009-12-18 | 組織因子経路阻害因子（ｔｆｐｉ）に対する抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8618263B2 (OSRAM) |
| EP (1) | EP2379599B1 (OSRAM) |
| JP (1) | JP5791512B2 (OSRAM) |
| CN (1) | CN102300876A (OSRAM) |
| TW (1) | TW201026329A (OSRAM) |
| WO (1) | WO2010072687A1 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2745317C (en) * | 2008-12-22 | 2019-03-05 | Ida Hilden | Antibodies against tissue factor pathway inhibitor |
| AU2011223710B2 (en) | 2010-03-01 | 2016-04-14 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI) |
| EP2588499B1 (en) * | 2010-06-30 | 2020-04-08 | Novo Nordisk A/S | Antibodies that are capable of specifically binding tissue factor pathway inhibitor |
| US9228022B2 (en) | 2010-06-30 | 2016-01-05 | Novo Nordisk A/S | Antibodies that are capable of specifically binding tissue factor pathway inhibitor |
| WO2014140240A1 (en) | 2013-03-15 | 2014-09-18 | Novo Nordisk A/S | Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor |
| US10231993B2 (en) | 2013-06-27 | 2019-03-19 | University Of Washington Through Its Center For Commercialization | Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders |
| EP3022228B1 (en) * | 2013-07-19 | 2019-02-27 | Novo Nordisk A/S | Antibodies recognizing the n-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity |
| ES2905085T3 (es) * | 2014-09-17 | 2022-04-07 | Novo Nordisk As | Anticuerpos que pueden unirse a dos epítopos en el inhibidor de la vía del factor tisular (1-161) |
| EP4279128A3 (en) * | 2015-02-25 | 2024-02-28 | Mogam Institute for Biomedical Research | Novel antibody binding to tfpi and composition comprising the same |
| JP6664467B2 (ja) | 2015-08-19 | 2020-03-13 | ファイザー・インク | 組織因子経路インヒビター抗体およびその使用 |
| US20210395391A1 (en) | 2018-10-11 | 2021-12-23 | Pfizer Inc. | Dosage Regimen for TFPI Antagonists |
| CN112442127A (zh) * | 2019-08-29 | 2021-03-05 | 苏州康宁杰瑞生物科技有限公司 | 针对tfpi的单克隆抗体 |
| WO2025124481A1 (zh) * | 2023-12-13 | 2025-06-19 | 苏州康宁杰瑞生物科技有限公司 | Tfpi抗体用于治疗血友病 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0539975A1 (en) | 1991-10-31 | 1993-05-05 | Teijin Limited | Method for immunological assay of free lipoprotein-associated coagulation inhibitor (LACI) and kit therefor |
| JPH0875736A (ja) * | 1994-09-06 | 1996-03-22 | Chemo Sero Therapeut Res Inst | ヒト組織因子凝固系インヒビターの定量法 |
-
2009
- 2009-12-18 JP JP2011541487A patent/JP5791512B2/ja not_active Expired - Fee Related
- 2009-12-18 CN CN2009801555207A patent/CN102300876A/zh not_active Withdrawn
- 2009-12-18 US US13/140,840 patent/US8618263B2/en not_active Expired - Fee Related
- 2009-12-18 WO PCT/EP2009/067566 patent/WO2010072687A1/en not_active Ceased
- 2009-12-18 EP EP09793538.1A patent/EP2379599B1/en not_active Not-in-force
- 2009-12-22 TW TW098144131A patent/TW201026329A/zh unknown
-
2013
- 2013-08-28 US US14/012,204 patent/US20130344090A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012513193A5 (OSRAM) | ||
| JP2012505912A5 (OSRAM) | ||
| NO20083793L (no) | Antistoffer mot amyloid-beta peptid | |
| RU2015120804A (ru) | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений | |
| WO2008101985A3 (en) | Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization | |
| PH12019500644A1 (en) | Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections | |
| JP2018168176A5 (OSRAM) | ||
| JP2016529229A5 (OSRAM) | ||
| EA201892184A1 (ru) | Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора | |
| JP2016504275A5 (OSRAM) | ||
| JP2016521688A5 (OSRAM) | ||
| NZ591130A (en) | Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof | |
| JP2008508859A5 (OSRAM) | ||
| RU2534564C3 (ru) | Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii | |
| NZ599193A (en) | Siglec 15 antibodies in treating bone loss-related disease | |
| WO2010017196A3 (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
| EA201301107A1 (ru) | Моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
| EA201290525A1 (ru) | Новые антитела-антагонисты, их fab-фрагменты против gpvi и способы их применения | |
| EP3747457A3 (en) | Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases | |
| JP2018512124A5 (OSRAM) | ||
| JP2012188436A5 (OSRAM) | ||
| JP2013520996A5 (OSRAM) | ||
| EP2467167A4 (en) | APTAMERS FOR A TISSUE FACTOR PATHWASHER AND THEIR USE AS A THERAPY AGENT FOR BLOODING DISORDER | |
| EA200600735A1 (ru) | Нуклеиновые кислоты, специфично связывающие биоактивный грелин | |
| JP2014510730A5 (OSRAM) |